(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

THERAVISION

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

THERAVISION

ST13

US500000086198574

Class

10

Filing

86198574

Registration

4956376

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

39

Latest update

05/12/2025

Trademark type

Word

Nice classes

10

Filing date

02/20/2014

Registration date

05/10/2016

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

04/14/2022

Last transaction

05/12/2025

Responsible office

United States Patent and Trademark Office

Status code

702

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

09/04/2013

First use in commerce

09/04/2013

Drawing code

4

Owner type

03

Owner location

Savoy, IL

Examiner

JACKSON, WILLIAM

Law office

M80

Current location

TMO LAW OFFICE 117

Holders and representatives

Holders

Acoustic Medsystems, Inc.

Representatives

Matt C. Deering MEYER CAPEL, A PROFESSIONAL CORPORATION

Technical classification

Nice Classes

Class 10

Vienna Codes

No Vienna codes available.

Goods and services

Class 10

Automated medical ultrasound system for use in therapy and image guidance

Publications

History of USPTO decisions and trademark events.

39 publications found

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

05/11/2025

NA85

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED

04/14/2022

C15A

REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

04/14/2022

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

04/12/2022

E815

TEAS SECTION 8 & 15 RECEIVED

10/31/2021

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

05/10/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

05/10/2016

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

04/08/2016

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

04/07/2016

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

03/22/2016

SUPC

STATEMENT OF USE PROCESSING COMPLETE

03/21/2016

EX3G

SOU EXTENSION 3 GRANTED

03/21/2016

IUAF

USE AMENDMENT FILED

03/03/2016

EXT3

SOU EXTENSION 3 FILED

03/03/2016

EEXT

SOU TEAS EXTENSION RECEIVED

03/03/2016

EISU

TEAS STATEMENT OF USE RECEIVED

03/03/2016

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

09/29/2015

EX2G

SOU EXTENSION 2 GRANTED

09/28/2015

EXT2

SOU EXTENSION 2 FILED

09/15/2015

EEXT

SOU TEAS EXTENSION RECEIVED

09/15/2015

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

04/28/2015

EX1G

SOU EXTENSION 1 GRANTED

04/27/2015

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

04/22/2015

EXT1

SOU EXTENSION 1 FILED

03/16/2015

EEXT

SOU TEAS EXTENSION RECEIVED

03/16/2015

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

09/16/2014

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

07/22/2014

PUBO

PUBLISHED FOR OPPOSITION

07/22/2014

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

07/02/2014

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

06/13/2014

ALIE

ASSIGNED TO LIE

06/12/2014

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

05/30/2014

XAEC

EXAMINER'S AMENDMENT ENTERED

05/30/2014

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

05/30/2014

GNEA

EXAMINERS AMENDMENT E-MAILED

05/30/2014

CNEA

EXAMINERS AMENDMENT -WRITTEN

05/30/2014

DOCK

ASSIGNED TO EXAMINER

05/28/2014

MPMK

NOTICE OF PSEUDO MARK E-MAILED

03/06/2014

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

03/05/2014

Continuous trademark protection

Get notified about every new filing that threatens THERAVISION or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.